Tenatumomab Biosimilar Radiolabelled Antibody (TNC) for Research

Cat No.: GMP-Bios-ab-561

Pre-Made Tenatumomab biosimilar, Whole mAb Radiolabelled, Anti-TNC Antibody: Anti-150-225/DFNA56/GMEM/GP/HXB/JI/TN/TN-C therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tenatumomab is a monoclonal antibody designed for the treatment of cancer.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-561-1mg 1mg
GMP-Bios-ab-561-10mg 10mg
GMP-Bios-ab-561-100mg 100mg
GMP-Bios-ab-561-xmg ＞100mg



Product Details

Products Name (INN Index) Pre-Made Tenatumomab biosimilar, Whole mAb Radiolabelled, Anti-TNC Antibody: Anti-150-225/DFNA56/GMEM/GP/HXB/JI/TN/TN-C therapeutic antibody
INN Name Tenatumomab
TargetTNC
FormatWhole mAb Radiolabelled
DerivationMouse
Species ReactivityHuman
CH1 IsotypeIgG2b
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2007
Year Recommended2008
Companiessigma-tau SpA
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedCancer
Development Techna



About target - TNC

1. Protein Tenascin

2. Gene TNC

3. Organism Homo sapiens (Human)

Function
Extracellular matrix protein implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity as well as neuronal regeneration. Promotes neurite outgrowth from cortical neurons grown on a monolayer of astrocytes. Ligand for integrins alpha-8/beta-1, alpha-9/beta-1, alpha-V/beta-3 and alpha-V/beta-6. In tumors, stimulates angiogenesis by elongation, migration and sprouting of endothelial cells (PubMed:19884327).